Patient leaflets and SmPCs, drug interaction checker, official and paediatric dosages, pregnancy and breastfeeding guidance, and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official and paediatric dosages, pregnancy and breastfeeding guidance, and NHS pharmacy opening hours — all in one place.
Metalyse is a powder for solution for injection.
Metalyse belongs to a group of medicines called thrombolytic agents. These medicines help to dissolve blood clots. Tenecteplase is a recombinant fibrin-specific plasminogen activator.
Metalyse is used in adults to treat stroke caused by a blood clot in an artery of the brain (acute ischaemic stroke) when it has been less than 4.5 hours since you were last seen without the symptoms of your current stroke.
Metalyse will not be prescribed and given by your doctor
- if you have previously had a sudden life-threatening allergic reaction (severe hypersensitivity) to tenecteplase, to any of the other ingredients of this medicine (listed in section 6) or to gentamicin (a trace residue from the manufacturing process). If treatment with Metalyse is nevertheless considered to be necessary, facilities for reanimation should be immediately available in case of need;
if you have, or have recently had, an illness that increases your risk of bleeding (haemorrhage), including:
¢ a bleeding disorder or tendency to bleed (haemorrhage);
* very high, uncontrolled blood pressure;
* ahead injury;
¢ inflammation of the lining around the heart (pericarditis); inflammation or infection of the heart valves (endocarditis);
* severe liver disease;
* varicose veins in the gullet (oesophageal varices);
¢ gastric ulcer or ulcers in the gut;
* abnormality of the blood vessels (e.g. an aneurysm);
* certain tumours;
¢ bleeding within the brain or skull;
- if you are taking tablets/capsules used to "thin" the blood (anti-coagulants), unless appropriate test confirmed no clinically relevant activity of such medicine;
- if you have a very severe stroke;
- if your stroke is causing only minor symptoms;
- if the symptoms are rapidly improving before receiving Metalyse;
- if your thromboplastin time (a blood test to see how well your blood clots) is abnormal. This test can be abnormal if you have received heparin (a medicine used to "thin" the blood) within the previous 48 hours;
- if you are diabetic and have ever had a stroke before;
- if you have had a stroke within the last three months;
- if the number of blood platelets (thrombocytes) in your blood is very low;
- if you have a very high blood pressure (above 185/110) which can only be reduced by injection of medicines;
- if the amount of sugar (glucose) in your blood is very low (under 50 mg/dL) or very high (over 400 mg/dL);
- if you have recently had major surgery including surgery to your brain or spine;
- if you have recently had a biopsy (a procedure for obtaining a tissue specimen);
- if you have an inflamed pancreas (pancreatitis).
Warnings and precautions Your doctor will take special care with Metalyse
- if you have had any allergic reaction other than a sudden life-threatening allergic reaction (severe hypersensitive) to tenecteplase, to any of the other ingredients of this medicine (listed in section 6) or to gentamicin (a trace residue from the manufacturing process);
- if you have or have recently had any other conditions that increase your risk of bleeding, such as:
- anintramuscular injection - asmall injury such as a puncture of major vessels;
- if you are aged over 80 years, you may have a poorer outcome regardless of treatment with Metalyse.
However, in general the benefit-risk of Metalyse in patients over 80 years is positive and age alone is not a barrier to treatment with Metalyse;
- if you have been given cardiopulmonary resuscitation (chest compressions) for more than 2 minutes duration;
- if you have ever had a stroke caused by a blood clot in an artery of the brain (ischaemic stroke);
- if you have a heart valve abnormality (e.g. mitral stenosis) with an abnormal heart rhythm (e.g. atrial fibrillation);
- if you have high blood pressure;
- if you had cramps (convulsions) when your stroke started;
- if you are diabetic;
- ifthe signs of acute ischaemic stroke continues after normalisation of low sugar amount in your blood, your doctor may still consider thrombolytic treatment;
- if you have ever received Metalyse before.
Children and adolescents The use of Metalyse in children and adolescents up to the age of 18 years is not recommended.
Other medicines and Metalyse
Tell your doctor or pharmacist if you are taking, have
recently taken or might take any other medicines. It is
particularly important that you tell your doctor if you are
taking or have recently taken:
- any medicines which are used to "thin" the blood
- certain medicines used to treat high blood pressure (ACE inhibitors).
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before you are given this medicine.
Metalyse contains polysorbate 20
This medicine contains 2.0 mg of polysorbate 20 in each 25 mg vial. Polysorbates may cause allergic reactions. Tell your doctor if you have any known allergies.
How is Metalyse administered
The doctor calculates your dose of Metalyse according to your bodyweight, based on the following scheme:
Bodyweight less |60 to 70/70 to 80/80 to 90/above 90 (kg) than 60
Metalyse (U)| 3000 | 3500 | 4000 | 4500 | 5000
Metalyse is given by a single injection into a vein by a doctor who is experienced in the use of this type of medicinal product.
Your doctor will give Metalyse as soon as possible after your stroke starts as a single dose.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The side effects described below have been experienced by people given Metalyse:
Very common (may affect more than 1 in 10 people):
- Bleeding
- Bleeding in the brain (cerebral haemorrhage). Death or permanent disability may occur following bleeding in the brain or other serious bleeding events
Common (may affect up to 1 in 10 people):
- Bleeding at the injection or puncture site
- Nosebleeds
- Genitourinary bleeding (you may notice blood in your urine)
- Bruising
- Gastro-intestinal bleeding (e.g. bleeding from the stomach or bowel)
Uncommon (may affect up to 1 in 100 people): - Internal bleeding in the abdomen (retroperitoneal bleeding) - Bleeding in the eyes (eye haemorrhage)
eye . Mandatory in In-process control code specification File information 1D Orintfil P Pp rintfile Technical information Control Issue date of TD: 04.12.2024 Yes Yes Code Type: 128a PPM SKU: P057492 No Yes Issue date of artwork: 16/JUL/2025 No Yes pw ' 5 04. Print colors: PAN Black No Yes a 9757-0 = MASS A 23mm MASS B~ 1,59mm Mat. No. Pack. Site: P057492-003 No Yes MASS C~ max.43mm Min. font size: 11 pt MASS D_= 0,5mm Legend case version: V5.0 01/Jan/2021 (please do not change or remove it)
Technical colours - not for printing
BI-Diecut-Legendcase | Free area
Gluepoints
Additional Requirements of Packaging site
Template name: PI_680x475_ 40x53
| Index: 3.0
Only for Bl-internal use, Template according to Drawing no.: SP-14-0103-001-B
Rare (may affect up to 1 in 1 000 people):
- Low blood pressure (hypotension) Bleeding in the lungs (pulmonary haemorrhage) Hypersensitivity (anaphylactoid reactions) e.g. rash, hives (urticaria), difficulty breathing (bronchospasm)
- Bleeding into the area surrounding the heart (haemopericardium)
- Blood clot in the lung (pulmonary embolism) and in the vessels of other organ systems (thrombotic embolisation)
Not known (frequency cannot be estimated from the available data):
- Fat embolism (clots consisting of fat)
- Nausea
- Vomiting
- Body temperature increased (fever)
- Blood transfusions as consequence of bleedings
In case of bleeding in the brain events related to the nervous system have been reported e.g. drowsiness (somnolence), speech disorders, palsy of parts of the body (hemiparesis) and fits (convulsions).
Reporting of side effects
If you get any side effects, talk to your doctor or nurse.
This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.
Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store
Do not use this medicine after the expiry date which is stated on the label and carton after EXP.
Do not store above 30 °C. Keep the container in the outer carton in order to protect from light.
Once Metalyse has been reconstituted it may be stored for 24 hours at 2-8 °C and 8 hours at 30 °C. However, for microbiological reasons your doctor will normally use the reconstituted solution for injection immediately.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away
medicines you no longer use. These measures will help protect the environment.
- The active substance is tenecteplase.
- Each vial contains 5 000 units (25 mg) of tenecteplase.
When reconstituted with 5 mL water for injection each mL contains 1 000 U tenecteplase. The other ingredients are arginine, concentrated phosphoric acid (E 338) and polysorbate 20 (E 432). Gentamicin is contained as trace residue from the manufacturing process
What Metalyse looks like and contents of the pack
The carton contains one vial with a lyophilised powder with 25 mg tenecteplase,
Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder
Boehringer Ingelheim International GmbH Binger Strasse 173
55216 Ingelheim am Rhein
Germany
Manufacturer
Boehringer Ingelheim Pharma GmbH & Co. KG Birkendorfer Strasse 65
88397 Biberach/Riss
Germany
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
United Kingdom Boehringer Ingelheim Ltd. Tel: +44 1344 424 600
This leaflet was last revised in 07/2025.
Metalyse 5 000 units (25 mg) powder for solution for injection comes as powder containing 000 units. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Metalyse 5 000 units (25 mg) powder for solution for injection is tenecteplase.
Medicines with the same active substance include: Metalyse 10,000 units (50 mg) powder and solvent for solution for injection. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Metalyse 5 000 units (25 mg) powder for solution for injection, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Ask anything about Metalyse 5 000 units (25 mg) powder for solution for injection. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.